This is not the most recent version of the article. View current version (30 DEC 2013)

Intervention Protocol

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

  1. Marc Arbyn1,*,
  2. Andrew Bryant2,
  3. Philippe Beutels3,
  4. Pierre PL Martin-Hirsch4,
  5. Evangelos Paraskevaidis5,
  6. Elke Van Hoof6,
  7. Marc Steben7,
  8. Youlin Qiao8,
  9. Fang-Hui Zhao8,
  10. Achim Schneider9,
  11. Andreas Kaufmann10,
  12. Joakim Dillner11,
  13. Lauri Markowitz12,
  14. Allan Hildesheim13

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 13 APR 2011

Assessed as up-to-date: 2 MAR 2011

DOI: 10.1002/14651858.CD009069


How to Cite

Arbyn M, Bryant A, Beutels P, Martin-Hirsch PPL, Paraskevaidis E, Van Hoof E, Steben M, Qiao Y, Zhao FH, Schneider A, Kaufmann A, Dillner J, Markowitz L, Hildesheim A. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.

Author Information

  1. 1

    Scientific Institute of Public Health, Unit of Cancer Epidemiology, Brussels, Belgium

  2. 2

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  3. 3

    Vaccine & Infectious Disease Institute (VAXINFECTIO), Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Antwerp, Belgium

  4. 4

    Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust, Gynaecological Oncology Unit, Preston, Lancashire, UK

  5. 5

    Ioannina University Hospital, Department of Obstetrics and Gynaecology, Ioannina, Greece

  6. 6

    Scientific Institute of Public Health, Belgian Cancer Centre, Brussels, Belgium

  7. 7

    Direction Des Risques Biologiques et de la Santé au Travail, Montréal (Québec), Canada

  8. 8

    Cancer Institute, Department of Cancer Epidemiology, Beijing, China

  9. 9

    Department of Gynecology and Gynecologic Oncology, Berlin, Germany

  10. 10

    Charite Campus Benjamin Franklin, Gynäkologische Tumorimmunologie, Berlin, Germany

  11. 11

    WHO HPV LabNet Global Reference Laboratory, Department of Clinical Microbiology, Stockholm, Sweden

  12. 12

    Centers for Disease Control and Prevention, ESB/DSTDP/NCHHSTP, Atlanta, GA, USA

  13. 13

    National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, MD, USA

*Marc Arbyn, Unit of Cancer Epidemiology, Scientific Institute of Public Health, Juliette Wytsmanstreet 14, Brussels, B-1050, Belgium. Marc.Arbyn@wiv-isp.be.

Publication History

  1. Publication Status: New
  2. Published Online: 13 APR 2011

SEARCH

This is not the most recent version of the article. View current version (30 DEC 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.